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H. -P. Beck, I. Felger, W. Huber, S. Steiger, T. Smith, Swiss Tropical Institute, Basel, Switzerland; University of Witten-
Herdecke, Witten, Germany; Unidad de Epidemiologia y Bioestadistica,N. Weiss, P. Alonso, and M. Tanner
Hospital Clinic i Provincial, Barcelona, Spain
In the first phase III efficacy trial of the malaria vaccine SPf66 in Africa, MOIs in SPf66- and
placebo-vaccinated children were analyzed by polymerase chain reaction–restriction fragment
length polymorphism of the Plasmodium falciparum merozoite surface antigen 2 (MSA2). MOIs
were significantly reduced in asymptomatic vaccine recipients compared with those in asymptomatic
placebo recipients; however, no differences were observed among symptomatic children in the
vaccine and control groups. These results show that immunization with SPf66 modulates the course
of naturally occurring infections, as reflected by reduced MOIs. In placebo recipients, however, there
was a significant negative correlation between numbers of infecting genotypes, as identified by
MSA2, and morbidity. Asymptomatic placebo recipients had an average of 5 concurrent infections,
whereas children with clinical cases had an average of 3.4 infections. These data provide further
evidence that premunition from concurrent infections is important in immunity against clinical
malaria. No such effect of multiple infections was found in the vaccinated group.
The malaria vaccine SPf66 has been extensively tested in to be highly polymorphic, yet all identi®ed alleles could be
grouped into the two allelic families, FC27 and 3D7 [8].South American populations, with a variable degree of ef®cacy
against clinical Plasmodium falciparum malaria [1]. In phase MSA2 is a useful marker in studies of diversity in Plasmo-
dium populations and has been used in several other studiesIII trials against clinical malaria, the vaccine had an ef®cacy
of 39% in Colombia [2], 55% in Venezuela [3], and 66% in an attempt to describe parasite diversity within endemic
populations [9±12]. We recently reported different age distri-in Ecuador [4], three countries with low malaria endemicity.
Recently, SPf66 was tested in children and infants in malaria- butions of the two allelic families of MSA2 in a malaria-
exposed population in Papua New Guinea [10]. However, sinceendemic areas of Africa. The vaccine had an estimated protec-
tive ef®cacy of 31% against clinical episodes in 1- to 5-year- multiple infections are relatively infrequent in Papua New
Guinea, only limited investigation of the effects of MOIs onold Tanzanian children in an area where malaria transmission
is intense and perennial [5]. In The Gambia, no signi®cant parasite density and morbidity was possible.
From studies conducted in areas with different endemicity,protection was observed in a trial involving infants who were
6±11 months old at the time of the ®rst vaccine dose and it appears that numbers and multiplicity of concurrent P. falcip-
arum infections as determined by MSA2 analysis could bewho were exposed to seasonal malaria [6]. The African trials,
however, were not completely comparable, primarily because markers for exposure [10±13]. In hyperendemic areas, such as
Senegal or Tanzania, multiple infections have been observedof the different endemicity situations but also due to trial de-
signs [6]. A recent SPf66 trial in northwestern Thailand also with high frequencies, and MOIs were high [13, 14]. In holoen-
demic areas, such as lowland areas of Papua New Guinea,showed no vaccine ef®cacy [7].
To analyze the effect of vaccination with SPf66 on parasite multiple infections were observed less frequently, and multi-
plicity was low [10, 15, 16]. In this study, we investigated P.diversity and MOI, we genotyped P. falciparum infections from
vaccine and placebo recipients from the Tanzanian trial for the falciparum MOIs in vaccine and placebo recipients.
merozoite surface antigen 2 (MSA2). MSA2 has been shown
Material and Methods
Samples. Samples described in this study were collected dur-
Received 12 April 1996; revised 16 October 1996. ing a phase III randomized trial of the SPf66 malaria vaccine in
All experiments involving humans followed the guidelines of conduct of Idete village, Kilombero District, Tanzania [5]. Details of the trial
clinical research and were performed after informed consent of the children's
design have been presented elsewhere [17]. In brief, children whoparents or guardians. Research and ethical clearance was granted by the Tanza-
were 1 to 5 years old at the time of the ®rst dose of placebo ornian Commission for Science and Technology (NSR/RCA 90).
Financial support: All participating institutions, Swiss Agency for Develop- vaccine were treated with sulfadoxine-pyrimethamine (Fansidar;
ment and Cooperation, and Jubilee Foundation of the Swiss Tropical Institute. Roche, Basel, Switzerland) to clear parasitemia at each of the
Reprints or correspondence: Dr. Hans-Peter Beck, Swiss Tropical Institute,
three immunizations. Reinfection after treatment was followed atSocinstrasse 57, CH 4002 Basel, Switzerland.
repeated cross-sectional surveys in a subgroup of children, and
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clinical malaria was monitored by case detection at the Idete dis-q 1997 by The University of Chicago. All rights reserved.
0022±1899/97/7504±0026$01.00 pensary [5, 18]. This study concerns only samples collected subse-
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quent to the third dose of vaccine or placebo at week 26 of the increase with time. At week 30, 2 asymptomatic placebo recipi-
trial protocol. ents had a mean MOI of only 1.5 (SE  0.5), but by week 50
Clinical malaria cases. Clinical malaria was de®ned as axil- it had increased to 4.5 (SE  0.4), and at week 73, the average
lary temperature of ⁄37.57C and a density of asexual parasites of number of MSA2 genotypes per sample in placebo recipients5000/mL by conventional light microscopy [5]. This parasite was 5.5. In clinical malaria cases, there was little difference
density cutoff was lower than that used in the primary estimates
between surveys (data not shown). There was a positive corre-
of vaccine ef®cacy [5]. This less-speci®c case de®nition was cho-
lation in asymptomatic vaccinated children with the elapsedsen for the present analyses because insuf®cient samples with para-
time after sulfadoxine-pyrimethamine treatment and the num-site densities of 20,000/mL were available from vaccine recipi-
ber of infections (Spearman's rank correlation [rs]  .52; P ents with clinical episodes [17].
.001). In all 4 groups, there was no statistically signi®cant age-For each vaccine recipient who provided ⁄1 sample during a
clinical malaria episode, only 1 such sample was selected randomly dependency of multiplicity when corrected for elapsed time
and included in the present study. These samples were strati®ed after treatment (for asymptomatic placebo recipients, partial rs
according to the nearest, in time, cross-sectional survey (at week  0.09; for asymptomatic vaccine recipients, partial rs  .09;
30, 50, or 73 of the protocol [17]). From each of these time periods, for symptomatic placebo recipients, partial rs  .07; and for
samples from clinical episodes of placebo recipients were also symptomatic vaccinated children, partial rs  0.18). In symp-
included. Again, only 1 sample (chosen at random within the above tomatic cases in both vaccine and placebo recipients, multiplic-
constraints) from each child was analyzed.
ity was completely independent of the elapsed time after treat-
Community controls. Control samples were selected from
ment.cross-sectional surveys done as part of the vaccine trial. Only
The frequency and distribution of multiple MSA2 infectionssamples positive for asexual-stage P. falciparum by microscopy
is shown in table 2. PCR-RFLP analysis of MSA2 not onlyand only those from children who were not represented among the
allowed enumeration of multiple infections but also identi®ca-cases were considered. The control samples were chosen to ensure
equal representation of each time period in cases and controls for tion of the two allelic families (FC27 or 3D7) [8] to which the
both placebo and vaccine recipients. Insofar as this was possible, individual alleles belonged (table 2). Twelve crossing-overs
controls were also selected to have the same age distributions as between MSA2 alleles of different allelic families as described
cases. However, because clinical malaria occurred predominantly by Ntoumi et al. [13] and Marshall et al. [22] were detected
in the youngest children [19], it was not possible to select enough by recombination of the family-speci®c restriction fragments.
control samples from children who were as young as the cases; These alleles are currently being analyzed by sequencing. For
therefore, some samples from older children were tested. Only 1
classi®cation of allelic families, we used the immunologically
sample was included from each child.
important repeat region, and all genotypes containing the FC27-Laboratory methods. For genotyping, DNA was isolated from
like 32-aa repeat were categorized as an FC27-like genotype.5 mL of blood in 4 M guanidine isothiocyanate containing 25 mM
The comparative analysis of numbers of infections in asymp-sodium-citrate, 0.2 M sodium-acetate, pH 4.4, 0.5% SDS, and 0.2
tomatic vaccine recipients and healthy placebo recipientsM b-mercaptoethanol. The mixture was phenol-treated once and
precipitated with isopropanol. For MSA2 genotyping, one-tenth of showed a signi®cant reduction of MOIs. In vaccinated children,
the DNA was ampli®ed by polymerase chain reaction (PCR), using the mean number of concurrent infections was 3.9/sample, and
the primers S2/S3 and S1/S4 for primary and nested PCR, respec- in placebo recipients it was 5.0/sample (P  .005, Wilcoxon
tively [20]. The PCR products subsequently were subjected to an Z  2.84). A reduction was also seen for the individual allelic
array of restriction enzymes, and the resulting fragments were families (table 2). In contrast, in clinical cases the mean number
separated on 12% polyacrylamide gels as described [21]. Figure of infections was similar in the vaccinated group and in the
1 is an example of the restriction fragment length polymorphism
placebo recipients (table 2). In neither group were levels of
(RFLP) pattern of 10 concurrent infections found in 1 sample.
parasitemia correlated with the overall MOIs, but a signi®cantRFLP patterns were assessed visually, and infections were enumer-
correlation with the number of FC27-like infections in asymp-ated independently by 3 researchers blinded to the source of the
tomatic vaccinees was observed (rs  0.27, P  .02). A similarsamples. Samples with inconsistent results were repeated and read
correlation was found in the placebo recipients (rs  0.32, Pagain.
 .005). There was no association with 3D7-like infections
and densities in asymptomatic vaccinees or placebo recipients,
suggesting that these infections generally made only a smallResults
contribution to the overall density. These ®ndings were not
signi®cantly affected by adjustment for age of the child or forIn total, 282 samples were genotyped for MSA2. Table 1
provides demographic and parasitologic data for the children the survey at which the sample was collected.
When asymptomatic and symptomatic placebo recipientsincluded in this analysis.
MSA2 was genotyped by PCR-RFLP in 135 samples from were compared, however, a strong negative association be-
tween risk of clinical malaria and the numbers of simultane-vaccinated children and in 147 samples from placebo recipi-
ents. After treatment with sulfadoxine-pyrimethamine, which ously infecting different parasites was observed, a ®nding that
could not be accounted for by age or time trends. A logisticwas required in the trial design, the MOIs showed a very rapid
/ 9d21$$ap23 02-24-97 19:25:57 jinfa UC: J Infect
923JID 1997;175 (April) SPf66 Vaccine and P. falciparum Multiplicity
Figure 1. Polymerase chain reaction ± re-
striction fragment length polymorphism (PCR-
RFLP) analysis of multiple MSA2 infections
in 1 blood sample of asymptomatic child,
showing RFLP pattern after Hinf I digest (right
lane of gel). Left lane of gel is 1-kb ladder
(GIBCO BRL, Eggenstein, Germany). Lane 1:
graphic representation of complete RFLP pat-
tern; lanes 2, 3: individual RFLP pattern of
FC27-like genotypes (D10, WOS12); lanes 4±
11: 3D7-like genotypes with characteristic 70-
and 108-bp fragments.
regression model was used to estimate the risk of being clini- In contrast, no signi®cant difference in numbers of infections
was observed among symptomatic and asymptomatic vacci-cally ill with malaria with multiple simultaneous infections.
Curves were ®tted for all MSA2 genotypes, for 3D7-like infec- nated children (table 2), and the risk of clinical episodes did
not vary with the number of simultaneous infections, as deter-tions only, and for FC27-like genotypes only (®gure 2). The
similar gradients of the curves suggested that multiplicity, not mined by MSA2 PCR (logistic regression: likelihood ratio x1
2
 0.29, P  .59) (®gure 2).any allelic family of the merozoite surface antigen, confers
protection. However, the statistical signi®cance of the regres-
sion was greater for 3D7-like genotypes (likelihood ratio x2 
Discussion
18.7, P  .001), due to the considerably larger diversity of
this allelic family, than for FC27-like genotypes (x2  6.8, For the present study, 282 children who were 1±5 years old
at the beginning of the study and living in an area of intenseP  .009), which displayed a smaller diversity.
Table 1. Demographic and parasitologic data for malaria-infected study children.
Placebo recipients Vaccinated children
Asymptomatic (n  76) Symptomatic (n  71) Asymptomatic (n  70) Symptomatic (n  65)
Mean age, years ({SD) 5.0 (1.5) 3.8 (1.2) 4.7 (1.5) 3.8 (1.4)
Mean elapsed time, days ({SD), after 3rd
sulphadoxine-pyrimethamine treatments 286 (87) 282 (73) 276 (98) 284 (63)
Geometric mean P. falciparum density
(95% con®dence interval) 3100* (2200±4300) 26,700² (21,000±34,200) 1600* (1100±2200) 17,500² (14,400±23,900)
NOTE. Children randomly selected from each group of phase III trial [5]. For symptomatic children, clinical malaria was de®ned as axillary temperature
⁄377C and 5000 asexual parasites/mL of blood.
* Signi®cantly different, Wilcoxon Z  2.66, P  .008.
² Signi®cantly different, Wilcoxon Z  2.16, P  .031.
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Table 2. Mean nos. of simultaneous malaria infections in vaccine and placebo recipients by morbidity.
Placebo recipients, Vaccine recipients,
Infection mean (SE) mean (SE) Z* P
MSA2
Asymptomatic children 4.97 (0.25) 3.90 (0.27) 2.84 .005
Symptomatic children 3.35 (0.25) 3.85 (0.27) 1.43 .15
FC27-like
Asymptomatic children 2.08 (0.15) 1.60 (0.14) 2.28 .02
Symptomatic children 1.55 (0.14) 1.66 (0.16) 0.50 .6
3D7-like
Asymptomatic children 2.89 (0.17) 2.30 (0.19) 2.46 .014
Symptomatic children 1.82 (0.18) 2.19 (0.18) 1.82 .07
NOTE. Clinical malaria was de®ned as axillary temperature ⁄377C and 5000 asexual parasites/mL of blood.
* Testing difference between vaccine and placebo recipients (Wilcoxon test).
malaria transmission were analyzed for infecting parasite geno- a high multiplicity of P. falciparum infections in this area [14].
Similar MOIs determined by use of a different technique weretypes. Infections with an average of 5 different genotypes were
identi®ed in asymptomatic placebo recipients, using highly sen- recently reported from Senegal [12, 13]. The MOIs and fre-
quency of multiple infections were much higher than those insitive PCR-RFLP for MSA2. In contrast, infections with only
3.9 MSA2 genotypes were identi®ed in asymptomatic vaccine studies conducted in Papua New Guinea using the identical
method [10, 15], likely as a consequence of the higher exposurerecipients. These data con®rm previous results demonstrating
Figure 2. Logistic regression line for risk of clinical malaria in relation to MOI. Observed odds relative to average MOI (l); ®tted logistic
regression (solid line); 95% con®dence limits (dashed lines). Odds ratios for placebo recipients with all multiple MSA2 infections (A), all
3D7-like genotype infections (B), and all FC27-like genotype infections (C). Odds ratios for vaccine recipients within all multiple MSA2
infections (D), all 3D7-like genotype infections (E), and all FC27-like genotype infections (F).
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to malaria in the Kilombero valley than in the study sites in An alternative explanation for the observed negative correla-
tion of multiple parasite infections with morbidity in nonvacci-Papua New Guinea [23].
In vaccinated children, MOIs were signi®cantly reduced. nated children is that a high MOI provides protection per se.
In support of our interpretation, a recent study in Papua NewThe reduction of multiplicity in asymptomatic P. falciparum
infections associated with SPf66 vaccination seems to be com- Guinea, in which the prospective risk of clinical malaria was
analyzed in relation to multiple infections, showed that childrenparable in magnitude to the effects on clinical episodes [5]
and on parasite densities [19]. There was no reduction in the with multiple infections had a lower prospective risk of clinical
malaria (Al-Yaman F, personal communication). There is evi-incidence of blood-stage infection after three doses of vaccine
[5], and SPf66 did not signi®cantly reduce the overall preva- dence that clinical malaria in children in endemic areas occurs
as a result of acquisition of a parasite with an antigen genotypelence of infection in the Tanzanian trial [19]. Hence, the re-
duced MOI in asymptomatic infections is likely to be a conse- to which they do not yet have immunity [16, 28]. As a child
ages, the repertoire of genotypes to which the immune systemquence of an increased rate of elimination of individual
infections. This would correspond to the reported results of the has been exposed increases, and thus the child becomes more
likely to be protected against any new infections [29].early SPf66 challenge trials [24, 25] in nonimmune hosts,
which indicated that SPf66 does not induce sterilizing immu- The results of the present study in placebo recipients suggest
that it is not only memory of previous infections but alsonity against P. falciparum but that some infections can be self-
limiting. It appears that this course may also be followed by that the repertoire of concurrent infections (premunition) may
determine the speci®city of effective immune mechanismsindividual infections in children with considerable previous
exposure and with multiple infections of parasites with different against new infections [30]. It appears that the process of acqui-
sition of premunition is probably highly dependent on the de-genotypes.
The observed differences in multiplicity between vaccine gree of endemicity and on the number of infective bites an
individual receives. Immunologic cross-protection between dif-and placebo recipients may be explained by an immune modu-
lation due to vaccination. In the absence of vaccination, low- ferent genotypes may also increase the acquisition of immunity.
In contrast to ®ndings in the placebo recipients, the numberdensity malaria infections can persist because natural immunity
to asexual stage parasites appears to be highly density-depen- of infections in vaccine recipients with clinical malaria was
very similar to that in asymptomatic vaccine recipients. Vacci-dent [23, 24]: The immune system is predominantly stimulated
by high-density infections, and low-grade parasitemia may be nation with SPf66 had apparently eliminated the effect of multi-
ple infections. This may be explained by differences in thetolerated. In semi-immune persons, the densities of many infec-
tions may thus be reduced to a low level, but infection is not course of an infection in vaccinated children, in whom the
acquisition of multiple infections may be slower and the elimi-completely eliminated. Unlike naturally stimulated immunity,
vaccine-induced immunity is in general not density-dependent nation of infections seems to be faster than in placebo recipi-
ents. But if immunity against individual genotypes takes some(i.e., the primary response does not depend on the intensity or
even on the existence of an infection). Our results with vaccine time to develop, the reduced duration of infections could inter-
fere with the development of premunition. Presumably, thisrecipients suggest that SPf66 may induce a response suf®cient
to control high-density infections and hence to prevent morbid- must be compensated for by the vaccine-induced protective
effect to control high-density parasitemia.ity while eliminating low-grade infections. This could result in
the observed reduction of MOIs in both groups. The possibility that the vaccine is speci®cally more active
against certain genotypes and that other genotypes graduallyThe signi®cant negative correlation between MOIs and mor-
bidity in placebo recipients is in agreement with ®ndings from accumulate must therefore still be considered, although to
date no signi®cant differences in MSA2 genotype frequenciesPapua New Guinea, where multiple infections were associated
with a reduced risk of clinical malaria [15]. One explanation for have been observed (data not shown). Due to the large poly-
morphism of MSA2, identi®cation of a shift in allele frequen-these ®ndings could be that in clinical malaria episodes, the
dominant parasite genotype may stimulate a complex cascade of cies at this locus would require large sample sizes. The possi-
ble selection for resistant genotypes in a vaccinated populationnonspeci®c responses, such as cytokine-mediated fever and re-
lease of nitric oxide or oxygen radicals, which have an antipara- must be considered and should be a priority question for
further investigation, which also should include additionalsitic effect [26, 27], eliminating nondominant genotypes or sup-
pressing them below the PCR detection limit. This would result polymorphic markers.
in a signi®cantly reduced MOI. Reduced multiplicity in children
with clinical episodes could have also been due to more frequent
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